Regenxbio (RGNX) Net Cash Flow (2014 - 2025)

Regenxbio's Net Cash Flow history runs 12 years deep, the most recent figure standing at -$24.3 million for Q4 2025.

• In Q4 2025, Net Cash Flow fell 2777.23% year-over-year to -$24.3 million; the TTM figure through Dec 2025 stood at -$23.1 million (down 200.24% YoY), while the FY2025 annual figure was -$23.1 million, down 200.24% from the prior year.
• Net Cash Flow was -$24.3 million for Q4 2025 at Regenxbio, down from -$20.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $117.5 million in Q4 2021 to a low of -$153.3 million in Q1 2022.
• Historically, Net Cash Flow has averaged -$15.2 million across 5 years, with a median of -$21.2 million in 2022.
• The sharpest annual moves came in 2021 and 2024: Net Cash Flow sank 45476.7% in 2021, then soared 392.07% in 2024.
• A 5-year view of Net Cash Flow shows it stood at $117.5 million in 2021, then plunged by 118.37% to -$21.6 million in 2022, then climbed by 13.17% to -$18.7 million in 2023, then surged by 104.85% to $909000.0 in 2024, then tumbled by 2777.23% to -$24.3 million in 2025.
• The last three Net Cash Flow figures came in at -$24.3 million (Q4 2025), -$20.8 million (Q3 2025), and -$50.5 million (Q2 2025), per Business Quant data.